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A B S T R A C T
Purpose
Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and
MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic
cancers have been described within the Lynch tumor spectrum. However, the age-specific cu-
mulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch
syndrome. Using a large data set from aworldwide collaboration, our aimwas to determine accurate
penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 variants.
Methods
A modified segregation analysis was conducted that incorporated both genotyped and non-
genotyped relatives, with conditioning for ascertainment to estimates corrected for bias. Hazard
ratios (HRs) and corresponding 95% CIs were estimated for each cancer site for mutation carriers
compared with the general population, followed by estimation of penetrance.
Results
In total, 284 families consisting of 4,878 first- and second-degree family members were included in
the analysis. PMS2mutation carriers were at increased risk for colorectal cancer (cumulative risk to
age 80 years of 13% [95%CI, 7.9% to 22%] for males and 12% [95%CI, 6.7% to 21%] for females)
and endometrial cancer (13% [95% CI, 7.0%–24%]), compared with the general population (6.6%,
4.7%, and 2.4%, respectively). There was no clear evidence of an increased risk of ovarian, gastric,
hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer.
Conclusion
Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial
cancer but not for any other Lynch syndrome–associated cancer. This finding justifies that PMS2-
specific screening protocols could be restricted to colonoscopies. The role of risk-reducing hys-
terectomy and bilateral salpingo-oophorectomy for PMS2 mutation carriers needs further
discussion.
J Clin Oncol 36:2961-2968. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Lynch syndrome is most commonly associated
with colorectal cancer and endometrial cancer.
However, when first described in 1913, the ob-
servation of the co-occurrence of gastric cancer
and endometrial cancer led to the initial iden-
tification of these families, underlining the
apparently diverse phenotype.1 The genetic
background of Lynch syndrome is now known,
and it is caused by heterozygous germline mu-
tations in one of the fourmismatch repair (MMR)
genes, MLH1, MSH2, MSH6, and PMS2, or
EPCAM deletions. The broad Lynch syndrome–
associated tumor spectrum includes not only
colorectal cancer and endometrial cancer but also
gastric, ovarian, small bowel, brain, urothelial
cell, skin, pancreas, prostate, and biliary tract
cancers.2,3 The involvement of germline MMR
mutations in the development of breast cancer is
still a subject of debate.4-7 Although the reported
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cumulative risk (penetrance) to age 70 years for these non-
colorectal, nonendometrial cancers in MMR gene mutation car-
riers is generally , 10%, mutation carriers still have a higher
risk relative to the general population.3 The Lynch syndrome–
associated tumor phenotypes and their penetrance could depend
on the type of MMR gene mutated or the specific variant.8,9
For heterozygous PMS2 mutation carriers, accurate estima-
tion of penetrance, especially for extracolonic cancers, has been
hampered both by difficulties in variant analysis related to the
existence of multiple pseudogenes and, perhaps more importantly,
by problems in identifying PMS2 mutation carriers because of
a markedly lower penetrance.10-12 Our previous study of pene-
trance for PMS2 mutation carriers, using 98 PMS2 families
ascertained through family cancer clinics in several European
countries, reported standardized incidence ratios for extracolonic
cancers and found an increased PMS2-related risk of cancer of the
small bowel, ovaries, renal pelvis and—most notably—of the
breast.11 Although that study presented the largest data set then
available, we were unable to generate reliable estimates of pene-
trance for these cancers because of their infrequency. In addition,
there was an ascertainment bias in this cohort because of the
recruitment via family cancer clinics. Another study from Iceland
reported significant increases in the risk of colorectal, endometrial,
and ovarian cancer for two pathogenic PMS2 founder variants.13
This study and others have reported relatively high prevalence of
PMS2 variants in the population,13-15 thus underlining the need for
PMS2-specific cancer risks. In the current study, we have expanded
the previous study database to 284 families, including several that
were identified through a population-based ascertainment, with
the aim of generating accurate penetrance estimates of colorectal,




European data set. Pedigree data on families with a segregating
pathogenic variant were originally collected between 2009 and 2012, as
previously described.11 These data were supplemented with PMS2
families identified between 2012 and 2017. Briefly, data were collected in
collaboration with the Netherlands Foundation for the Detection of
Hereditary Tumors and with clinical genetic departments in the Neth-
erlands, Norway, Germany, Sweden, Denmark, and Spain. Data col-
lection from patient records included demographic data, family
pedigrees, age and location of cancer diagnosis, polypectomy, and
hysterectomy if applicable. When available, clinical and pathologic di-
agnoses were confirmed using patient records. Data collection and
subsequent analysis protocols were approved by the local ethical review
board (Leiden University Medical Center Ethics Review Board, protocol
ID: P01.019).
Ohio State data sets. For the Ohio State data sets, the first set of
patients included both population-based patients with colorectal and
endometrial cancer from Columbus, Ohio, as described elsewhere,10,16-19
and patients with cancer identified at family cancer clinics with absence of
PMS2 only on immunohistochemistry. The second set of patients from
Ohio included only population-based patients with colorectal and en-
dometrial cancer from 50 hospitals throughout the state of Ohio, as de-
scribed previously.20 All patients provided informed consent (Ohio State
University Biomedical Sciences Institutional Review Board protocol IDs:
1999C0051, 1999C0245, and 2012C0123).
Colon Cancer Family Registry data set. The study cohort from the
Colon Cancer Family Registry has been described in detail elsewhere.21-23
Between 1998 and 2012, the Colon Cancer Family Registry recruited
families via population-based probands, recently diagnosed with colorectal
cancer, in state or regional population cancer registries in the United States
(Washington, California, Arizona, Minnesota, Colorado, New Hampshire,
North Carolina, and Hawaii), Australia (Victoria), and Canada (Ontario).
In addition, clinic-based probands were enrolled from multiple-case
families referred to family cancer clinics in the United States (Mayo
Clinic, Rochester, Minnesota and Cleveland Clinic, Cleveland, Ohio),
Canada (Ontario), Australia (Melbourne, Adelaide, Perth, Brisbane,
Sydney, and Newcastle), and New Zealand (Auckland). Probands were
asked for permission to contact their relatives to seek their enrollment in
the Cancer Family Registry (detailed in Newcomb et al21). Informed
consent was obtained from all study participants, and the study protocol
was approved by the institutional research ethics review board at each
registry. Information on demographics, personal characteristics, personal
and detailed family history of cancer in first- and second-degree relatives,
cancer-screening history, history of polyps, polypectomy, and other sur-
geries was obtained by questionnaires from all probands and participating
relatives. Participants were followed approximately every 5 years after
baseline to update this information. For the current study, each individual’s
lifetime cancer history was based on the most recent data (baseline or most
recent follow-up). Reported cancer diagnoses and age at diagnosis were
confirmed using pathology reports, medical records, cancer registry re-
ports, and death certificates, where possible.
Mutation Analysis and Clinical Variant Classification
Probands included in the cohorts were screened for point mutations
as well as large genomic rearrangements in the PMS2 gene (Data Sup-
plement). Relatives of probands were tested for the specific family mu-
tation. A detailed description of specific variants detected and their
classification can be found in the Data Supplement.
Statistical Analysis
For estimation of the hazard ratios (HRs) and age-specific cumulative
risks (penetrance), we used a modified segregation analysis.24 This ana-
lytical method is not subject to population stratification, can rigorously
adjust for ascertainment, and uses data on all study participants, whether
genotyped or not, thereby maximizing statistical power. Models were fitted
by the method of maximum likelihood with the statistical package
MENDEL 3.2.25 Estimates were appropriately adjusted for the ascer-
tainment of families using a combination of retrospective likelihood and
ascertainment-corrected joint likelihood. A conditional likelihood was
maximized, in which each pedigree’s data were conditioned on the pro-
band’s PMS2mutation status, cancer history, and ages of cancer diagnoses
(for population-based families) or on the proband’s PMS2mutation status
and the cancer history and ages of cancer diagnoses of all family members
(for clinic-based families).
For the purposes of analysis, we restricted included individuals to the
first- and second-degree relatives of the probands. Observation time
started at birth and stopped at age at diagnosis of cancer for affected, and
last known age or age at death for unaffected, family members. Because age
information for each family member was required for the pedigree
analysis, missing values were estimated using a defined protocol as follows.
If an exact age was unknown but an age range was provided, age was
estimated as the midpoint of that range. If age at diagnosis was unknown, it
was assumed to be the same as age at death (if the relative was deceased) or
the mean age at diagnosis for the specific cancer (if the relative was alive
and older than the mean age at diagnosis). For relatives for whom last
known age was unknown, ages were censored at the time they were last
known to be alive (eg, at the age at a cancer diagnosis). In the absence of
any age information, it was assumed that both parents of the proband were
born in the same year, that years of birth differed by 25 years in each
generation (eg, at birth of proband, parents were age 25 years and
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grandparents were age 50 years), and the ages of the siblings were the same.
As a sensitivity analysis, we conducted analyses with and without imputing
missing age; the results did not differ materially, and therefore results from
the nonimputed analysis were not shown in detail.
To calculate HRs, we used a likelihood-based approach in which age-
specific incidence for PMS2 mutation carriers was divided by that for
noncarriers. Incidence rates for noncarriers were assumed to be the same
as age-, sex-, and country-specific population incidence rates (Australia,
Canada, United States, The Netherlands, Germany) for the period 1998 to
2002, as obtained from Cancer Incidence in Five Continents.26 The period
of 1998 to 2002 was selected for analysis because it was the closest available
data set to the mean calendar year of cancer diagnoses in the sample. For
each cancer, the age at cancer diagnosis was modeled as a random variable
whose hazard was the relevant population incidence multiplied by
a cancer-specific HR. For colorectal cancer, HRs for carriers were assumed
to be continuous, piece-wise linear functions of age that are constant before
age 40 years; linear in the intervals 40 to 50, 50 to 60, and 60 to 70 years;
and constant after age 70 years. For all other cancer sites, HRs were as-
sumed to be independent of age. HRs for colorectal cancer, endometrial
cancer, and other cancers were estimated simultaneously to allow proper
adjustment for colorectal cancer–based ascertainment schemes when es-
timating the risks of noncolorectal cancers and to increase power (by
helping the model identify likely carriers from the placement of Lynch
syndrome–associated cancers within each family). HRs were assumed to be
independent of country of recruitment.
Age-specific cumulative risks (penetrance) of each cancer site for








where l(t) is the HR multiplied by the US population incidence.27
Corresponding CIs were calculated using a parametric bootstrap. More
specifically, 5,000 draws were taken from the multivariate normal dis-
tribution that the maximum likelihood estimates would be expected to
follow under asymptotic likelihood theory. For each age, corresponding
values of the cumulative risk were calculated, and the 95% CI for the
cumulative risks to that age were taken to be the 2.5th and 97.5th percentile
of this sample.
RESULTS
The final analysis included 284 families (211 from the European, 19
from the Ohio State, and 54 from the CCFR data set), with 1,904
first- and 2,974 second-degree family members, in whom 513 were
confirmed carriers (Table 1). The numbers and mean ages at
diagnosis of each cancer site in first- and second-degree relatives
are depicted in Table 2.
Colorectal Cancer
PMS2 mutation carriers were at increased risk of developing
colorectal cancer, with an HR depending on age and sex of the
mutation carrier: 6.51 (95% CI, 2.03 to 20.9) for males younger
than 40 years; 1.70 (95% CI, 0.89 to 3.24) for males older
than 70 years; 6.48 (95% CI, 2.24 to 18.8) for females younger than
40 years; and 2.23 (95% CI, 1.21 to 4.12) for females older than
70 years. Estimated cumulative risks of colorectal cancer to age
80 years for PMS2 mutation carriers were approximately 13%
(95% CI, 7.9% to 22%) for male carriers and 12% (95% CI, 6.7%
to 21%) for female carriers (general population 6.6% and 4.7%,
respectively; Fig 1A).
Gynecologic Cancers
PMS2 mutation carriers were also at small increased risk of
endometrial cancer, with an HR of 5.73 (95% CI, 2.98 to 11.0) and
estimated cumulative risk to age 80 years of approximately 13%
(95% CI, 7.0% to 24%), compared with females from the general
population (2.4%; Fig 1B). There was no clear evidence of increase
in the risk of ovarian cancer (HR, 1.52; 95% CI, 0.45 to 5.05; Fig 2).
Other Cancers
There was no clear increase in risk of gastric, hepatobiliary,
bladder, renal, brain, breast, or prostate cancer for PMS2mutation
carriers (HR for each cancer shown in Fig 2). There were too few
occurrences of small bowel cancer (n = 5) to generate an HR.
DISCUSSION
On the basis of the results from this large, international study of
heterozygous PMS2mutation carriers, the PMS2-associated Lynch
Table 1. Study Data Set Description
Individuals
No. of Family Members
Total Male Female
Probands (= No. of families) 284 149 136
FDR 1,904 953 951
SDR 2,974 1,487 1,487
Confirmed PMS2 mutation carriers 513 209 304
FDR 339 128 211
SDR 174 81 93
Confirmed PMS2 noncarriers 404 167 237
FDR 230 100 130
SDR 174 67 107
Abbreviations: FDR, first-degree relative; SDR, second-degree relative.
Table 2. No. and Mean Age at Diagnosis of Each Cancer Site in the FDRs and
SDRs of Probands
Cancer
FDR (n = 1,904) SDR (n = 2,974)
No.
Mean (SD) Age At
Diagnosis (years) No.
Mean (SD) Age at
Diagnosis (years)
Colorectal 116 59.6 (14.7) 112 62.7 (3.0)
Endometrial 33 55.7 (9.04) 21 54.8 (13.7)
Ovarian 9 52.2 (14.8) 5 41.6 (22.8)
Brain 18 42.3 (26.9) 10 56.3 (26.0)
Hepatobiliary 5 56.2 (13.6) 3 60.7 (9.87)
Gastric 14 57.8 (8.72) 11 57.3 (11.0)
Bladder 7 71.7 (14.5) 5 70.0 (14.3)
Breast 47 58.1 (12.0) 50 59.2 (13.5)
Prostate 19 70.7 (12.2) 24 69.8 (14.1)
Renal 7 65.0 (13.7) 5 61.2 (10.8)
Small bowel 4 45.0 (9.6) 1 38
Abbreviations: FDR, first-degree relative; SD, standard deviation; SDR, second-
degree relative.
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syndrome spectrum seems to be restricted to colorectal and en-
dometrial cancer only, underlining the distinct phenotype for
PMS2mutation carriers. We have also shown that PMS2mutation
carriers have much lower cancer risks compared with other MMR
gene mutation carriers.
The previous two studies of PMS2 mutation carriers have es-
timated cumulative risks to age 70 years of 11% to 20% for colorectal
cancer and 12% to 15% for endometrial cancer.10,11 Our current
analysis has confirmed that PMS2 carriers are at small increased risk
of colorectal and endometrial cancer. These penetrance estimates are
considerably lower than those for other MMR gene mutation car-
riers, which have been estimated at 35% to 55% for colorectal cancer
and 10% to 45% for endometrial cancer.3 A recent report from the
Prospective Lynch Syndrome Database described cancer risk and
survival for all patients with Lynch syndrome.7 This report included
124 PMS2 mutation carriers, with 524 observation years. The
findings support our study data, in that endometrial cancer was the
sole cancer type observed. Notably, colorectal cancer did not occur in
any of the PMS2mutation carriers undergoing regular colonoscopic
screening. This, together with our penetrance estimates, could justify
consideration of less-frequent colonoscopy screening for PMS2
mutation carriers. This, together with our low penetrance estimates
(Fig 1) could justify modification of the colonoscopy surveillance
protocol, for example starting at age 35 to 40 years, every 2 to 3 years,
similar to what has been proposed in the National Comprehensive
Cancer Network guidelines.28
The Prospective Lynch Syndrome Database showed that en-
dometrial cancer survival for all MMR pathogenic variant carriers
was excellent, with a 10-year survival of 93% (95% CI, 85% to
97%). The reported survival for ovarian cancer in patients with
Lynch syndrome was lower, at 74% (95%CI, 44% to 90%), but still
better than that for sporadic ovarian cancer cases. Current sur-
veillance guidelines advise that risk-reducing hysterectomy and
bilateral salpingo-oophorectomy should be considered in women
with Lynch syndrome, because transvaginal ultrasound with or


















































Fig 1. Cumulative risks (solid lines) and
corresponding 95% CIs (dotted lines) of
(A) colorectal cancer, and (B) endometrial
cancer for heterozygous PMS2 mutation
carriers, and for the US general population
(dashed lines). Blue and gold represent
males and females, respectively.
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and ovarian cancer and might not have a strong influence on
survival.29 The good survival rates for endometrial cancer, com-
bined with the data presented in the current study showing no
evidence of a clinically relevant increase in ovarian cancer risk for
PMS2 mutation carriers, raise questions about the justification of
risk-reducing hysterectomy and bilateral salpingo-oophorectomy,
which may be too rigorous in carriers of heterozygous pathogenic
PMS2 mutations.
In our previous study of patients with PMS2-associated
Lynch syndrome, we found increased standardized incidence
ratios (SIRs) for cancer of the small bowel, ovary, renal pelvis, and
breast.11 However, that study was limited by inclusion of con-
firmed mutation carriers identified through family cancer clinics
and a limited number of cancer events. The first factor in par-
ticular could have been a potential source of ascertainment bias,
because a strong family history of cancer and/or early-onset
disease increases the likelihood of inclusion and PMS2 testing.
In that report, we did not adjust for this potential ascertainment
bias when estimating SIRs for extracolonic cancers. Traditionally,
a strong family history of colorectal and endometrial cancers
prompted suspicion of Lynch syndrome, and consequently pa-
tients were tested for tumor MMR deficiency followed by MMR
gene mutation testing. Currently, family histories of other cancers
are increasingly being ascertained by clinical genetic centers for
additional evaluation as possible Lynch syndrome. Therefore, it is
important to take into account and adjust for ascertainment bias
when estimating risks of cancers other than colorectal or en-
dometrial cancer. Furthermore, pathogenic PMS2 variants are
relatively frequently observed using extensive gene panel testing
for women with hereditary breast and ovarian cancer.30-33
Nevertheless, we could not confirm an increased SIR for breast
cancer in the current study (HR, 1.30; 95% CI, 0.79 to 2.16), and
the discrepancy with earlier reports can probably be attributed to
a high prevalence of PMS2 (and MSH6) mutations in the general
population. Conversely, the relative infrequency of PMS2 variants
among patients with Lynch syndrome can be explained by the
milder phenotype, which makes ascertainment by family cancer
clinics less likely.
The current study is the largest to date, to our knowledge, in
estimation of cancer risks for heterozygous PMS2 mutation
carriers. Previous studies have shown that analyses of retrospective
data from clinic-based families (ie, ascertained because of family
history of cancer) without (statistical) adjustment can lead to
overestimation of cancer risks for mutation carriers.24,34,35 In the
current study, we used a high-level statistical approach to properly
adjust for such ascertainment bias. The modified segregation
method used data on all family members, regardless of whether
they were genotyped, thereby maximizing statistical power while
avoiding survival bias.
A potential limitation of the current study was the use of
unverified cancer diagnoses that were self- or proband-reported,
thus potentially affecting the accuracy of estimates. However,
previous studies showed a high probability of agreement between
proband-reported cancer status in first-degree relatives and the
validated report (for example, 95.4% [95% CI, 92.6 to 98.3] for
breast cancer, 83.3% [95% CI, 72.8 to 93.8] for ovarian cancer,
and 79.3% [95% CI, 70.0 to 88.6] for prostate cancer).36 Another
possible limitation is that our analysis did not take into account
a potential role for genetic or environmental modifiers of risk.
The existence of such modifiers is plausible, because a high degree
of variability in penetrance and phenotype has been observed,24
and modifiers of cancer risk such as lifestyle, genetic modifiers,
and phenotype-genotype correlations have been identified pre-
viously.37-40 Our study estimated cancer risks of all variants
combined; however, it is plausible that not all PMS2 variants
confer the same risk. A previous study in a selection of the
currently analyzed cohort investigated genotype-phenotype
correlations and found no difference in risk between the
group of variants with retained versus loss of RNA expression.40
However, this study did report that those carrying a variant with
loss of RNA expression were diagnosed with colorectal cancer on
average 9 years younger than those with retained expression. The
influence of these modifiers is still not well understood, especially
for PMS2 mutation carriers, although efforts are currently on-
going to better define such factors and their potential role in
modifying disease risk. Our study results highlight that studies of
penetrance modifiers should take the specific MMR gene mutated
into account.
In the current study, we analyzed the first data set, to our
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Fig 2. Hazard ratios (HRs) and correspond-
ing 95% CIs of extracolonic cancers for PMS2
mutation carriers.
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risk of each extracolonic cancer for PMS2 mutation carriers. Our
results show that PMS2 carriers are only at small increased risk of
colorectal and endometrial cancer. This underlines the importance
of gene-specific genetic counseling of patients with Lynch syn-
drome and the development of appropriate clinical guidelines.
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